The application of neuroimaging techniques to drug development

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 10, 1997, Pages 3-6

  Tamminga, Carol A ^a   Conley, Robert R ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLSPIPERONE; CARBON 11; CLOZAPINE; FLUORODEOXYGLUCOSE F 18; HALOPERIDOL; KETAMINE; NEUROLEPTIC AGENT; SODIUM CHLORIDE;

BRAIN FUNCTION; BRAIN INJURY; DRUG RESEARCH; HUMAN; IMAGE ANALYSIS; MENTAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN CHEMISTRY; CARBON RADIOISOTOPES; CEREBROVASCULAR CIRCULATION; DEOXYGLUCOSE; DIAGNOSTIC IMAGING; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; FLUORODEOXYGLUCOSE F18; HALOPERIDOL; HUMANS; KETAMINE; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; NEUROPHARMACOLOGY; RECEPTORS, DOPAMINE; SPIPERONE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0030809036     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Andreasen NC, Carson R, Diksic M, et al. Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. Schizophr Bull 1988;14:471-484
2. Holcomb HH, Cascella NG, Medoff DR, et al. PET-FDG test-retest reliability during a visual discrimination task in schizophrenia. J Comput Assist Tomogr 1993;17:704-709
3. Kotrla KJ, Weinberger DR. Brain imaging in schizophrenia. Ann Rev Med 1995;46:113-122
4. Tamminga CA, Thaker G, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992;49:522-530
5. Wong DF, Wagner HN, Tune LE, et al. Positron emission tomography reveals elevated dopamine D2 receptors in drug-naive schizophrenics. Science 1986;234:1558-1563
6. Nopoulos P, Torres I, Flaum M, et al. Brain morphology in first-episode schizophrenia. Am J Psychiatry 1995;152:1721-1723
7. Pearlson GD, Tune LE, Wong DF, et al. Quantitative D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia. Schizophr Bull 1993;19(4):783-795
8. Farde L, Nordstrom A-L, Wiesel F-A, et al. Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992;49: 538-544
9. 11C]N-methylspiperone. Psychiatry Res 1995; 61:67-83
10. 11C-N-methylspiperone. Psychiatry Res 1993;49:219-237
11. Holcomb HH, Cascella NG, Thaker GK, et al. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996;153:41-49
12. 11C]raclopride in man. Synapse 1995;20: 200-208
13. Tamminga CA, Conley RR, Wong DF. Human in vivo receptor imaging. Am J Psychiatry 1994;151:639
14. Kerwin RW, Pilowsky L, Munro J, et al. Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors. J Clin Psychiatry 1994;55(9, suppl B):57-62
15. Nordstrom A-L, Farde L, Halldin C. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 1993;110:365-367
16. Nordstrom A-L, Farde L, Nyberg S, et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-1449
17. Tamminga CA, Dannals RF, Frost JJ, et al. Neuroreceptor and neurochemistry studies with positron-emission tomography in psychiatric illness: promise and progress. In: Oldham JM, Riba MB, Tasman A, eds. Review of Psychiatry, vol 12. Washington, DC: American Psychiatric Press; 1993: 487-510
18. Lahti AC, Holcomb HH, Medoff DR, et al. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995;6: 869-892
19. Lahti AC, Koffel B, La Porte D, et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13:9-19